The 94th Annual Meeting of Japanese Society for Bacteriology

Presentation information

On-demand Presentation

5 Pathogens and Infectious Diseases (including Epidemiology)

[ODP5C] c. Prevention of Infection (Vaccinization and Other Methods)

[ODP-097] The anti-Helicobacter pylori colonization effect of serum and monoclonal antibody in the mice stomach

○Subsomwong Phawinee1,2, Ryota Otsubo1,3, Hitomi Mimuro1 (1Dept. Infect. Dis., RIMD, Osaka Univ., 2Dept. Microbiol. Immunol., Hirosaki Univ. Grad. Sch. Med., 3Toyama Pref. Inst. Pharm. Res., Toyama Univ.)

Helicobacter pylori is a Gram-negative bacterium that cause gastritis, ulcer and gastric cancer, and they persist in 50% of world populations stomach. The increased drug resistance to H. pylori made treatment harder. This study used a monoclonal antibody (mAb) to treat H. pylori infections. The C57BL/6J mice were infected with H. pylori PMSS1 strain for five weeks. The H. pylori specific-Igs were detected from the serum by ELISA assay, the H. pylori colonized in the stomach was counted and the B-cell population was analyzed by flow cytometry. The mAbs were generated by mice spleen infected with H. pylori using the hybridoma technique, the positive clones were tested for anti-colonization activities. H. pylori persisted in the stomach and induced high H. pylori-specific IgG titer at 4-5 weeks post-infection (WPI). The protective H. pylori colonization effect by the H. pylori infected mice serum was found at 5 WPI. We got two positive IgG and IgG2c-producing clones. The mAb from clone 1 bound with H. pylori cells and had the ability to control the infection in mice’s stomach. The humoral antibody and mAb from the infected mice have the prospects to reduce H. pylori. To develop passive antibody therapy in H. pylori infected patients, the epitope of H. pylori antigen and the variable region of mAb specific to H. pylori have to be characteristic.